Gilder Gagnon Howe & Co. LLC Purchases 520,859 Shares of Evolus, Inc. (NASDAQ:EOLS)

Gilder Gagnon Howe & Co. LLC raised its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 287.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 702,239 shares of the company's stock after acquiring an additional 520,859 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 1.11% of Evolus worth $7,753,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of Evolus by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock valued at $13,412,000 after purchasing an additional 3,969 shares during the last quarter. Schroder Investment Management Group boosted its stake in shares of Evolus by 2.5% during the 4th quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company's stock worth $11,330,000 after buying an additional 25,480 shares during the last quarter. Lord Abbett & CO. LLC grew its holdings in shares of Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock valued at $16,126,000 after acquiring an additional 188,685 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in shares of Evolus by 4.8% in the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock valued at $10,469,000 after acquiring an additional 43,381 shares in the last quarter. Finally, Altium Capital Management LLC increased its position in shares of Evolus by 93.0% in the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock valued at $7,562,000 after acquiring an additional 330,000 shares during the last quarter. Institutional investors own 90.69% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. BTIG Research initiated coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. Barclays raised their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Stock Up 0.9 %

EOLS stock opened at $11.65 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The business's 50 day simple moving average is $12.25 and its 200 day simple moving average is $12.92. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The firm has a market capitalization of $740.79 million, a PE ratio of -12.80 and a beta of 0.97.

Insider Activity

In other Evolus news, CFO Sandra Beaver sold 8,996 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares of the company's stock, valued at $2,301,710.58. This represents a 4.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the transaction, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock valued at $794,369 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.